Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib + pegylated interferon alpha-2b
- Development stage
- Unknown
- Lead developer
- Uppsala University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy consists of imatinib, a small molecule tyrosine kinase inhibitor, and pegylated interferon alpha-2b, a biologic immunomodulatory agent. It was investigated by Uppsala University and the Nordic CML Study Group for the treatment of newly diagnosed chronic-phase chronic myeloid leukemia (CML). Imatinib works by inhibiting the BCR-ABL fusion protein, the primary driver of CML, while pegylated interferon alpha-2b enhances the immune system's ability to target leukemic cells. A randomized phase 2 trial demonstrated that adding pegylated interferon alpha-2b to imatinib increased major molecular response rates compared to imatinib monotherapy, although a high percentage of patients discontinued the interferon component due to toxicity.
- Other names
- imatinib + PegIntronimatinib + peg-IFN alpha-2bimatinib and pegylated interferon
02
Targets
ABL1 myristoyl pocketKIT (c-KIT proto-oncogene receptor tyrosine kinase)IFNAR (Immune system modulation via type I interferon receptor)PDGFR (PDGFR family)
Beyond the preview
Go deeper on imatinib + pegylated interferon alpha-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib + pegylated interferon alpha-2b.